Cargando…

A Case Series of Metastatic Metaplastic Breast Carcinoma Treated With Anti-PD-1 Therapy

Metaplastic breast cancer is a rare and often chemo-refractory subtype of breast cancer with poor prognosis and limited treatment options. Recent studies have reported overexpression of programmed death ligand 1 (PD-L1) in metaplastic breast cancers, and there are several reports of anti-PD-1/L1 bei...

Descripción completa

Detalles Bibliográficos
Autores principales: Kim, Isaac, Rajamanickam, Venkatesh, Bernard, Brady, Chun, Brie, Wu, Yaping, Martel, Maritza, Sun, Zhaoyu, Redmond, William L., Sanchez, Katherine, Basho, Reva, McArthur, Heather, Page, David B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8217650/
https://www.ncbi.nlm.nih.gov/pubmed/34168978
http://dx.doi.org/10.3389/fonc.2021.635237
_version_ 1783710636185747456
author Kim, Isaac
Rajamanickam, Venkatesh
Bernard, Brady
Chun, Brie
Wu, Yaping
Martel, Maritza
Sun, Zhaoyu
Redmond, William L.
Sanchez, Katherine
Basho, Reva
McArthur, Heather
Page, David B.
author_facet Kim, Isaac
Rajamanickam, Venkatesh
Bernard, Brady
Chun, Brie
Wu, Yaping
Martel, Maritza
Sun, Zhaoyu
Redmond, William L.
Sanchez, Katherine
Basho, Reva
McArthur, Heather
Page, David B.
author_sort Kim, Isaac
collection PubMed
description Metaplastic breast cancer is a rare and often chemo-refractory subtype of breast cancer with poor prognosis and limited treatment options. Recent studies have reported overexpression of programmed death ligand 1 (PD-L1) in metaplastic breast cancers, and there are several reports of anti-PD-1/L1 being potentially active in this disease. In this case series, we present 5 patients with metastatic metaplastic breast cancer treated with anti-PD-1-based therapy at a single center, with 3 of 5 cases demonstrating a response to therapy, and one of the responding cases being a metaplastic lobular carcinoma with low-level hormone receptor expression. Cases were evaluated for PD-L1 expression, tumor infiltrating lymphocytes (TILs), DNA mutations, RNA sequencing, and T-cell receptor sequencing. Duration of the response in these cases was limited, in contrast to the more durable responses noted in other recently published reports.
format Online
Article
Text
id pubmed-8217650
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-82176502021-06-23 A Case Series of Metastatic Metaplastic Breast Carcinoma Treated With Anti-PD-1 Therapy Kim, Isaac Rajamanickam, Venkatesh Bernard, Brady Chun, Brie Wu, Yaping Martel, Maritza Sun, Zhaoyu Redmond, William L. Sanchez, Katherine Basho, Reva McArthur, Heather Page, David B. Front Oncol Oncology Metaplastic breast cancer is a rare and often chemo-refractory subtype of breast cancer with poor prognosis and limited treatment options. Recent studies have reported overexpression of programmed death ligand 1 (PD-L1) in metaplastic breast cancers, and there are several reports of anti-PD-1/L1 being potentially active in this disease. In this case series, we present 5 patients with metastatic metaplastic breast cancer treated with anti-PD-1-based therapy at a single center, with 3 of 5 cases demonstrating a response to therapy, and one of the responding cases being a metaplastic lobular carcinoma with low-level hormone receptor expression. Cases were evaluated for PD-L1 expression, tumor infiltrating lymphocytes (TILs), DNA mutations, RNA sequencing, and T-cell receptor sequencing. Duration of the response in these cases was limited, in contrast to the more durable responses noted in other recently published reports. Frontiers Media S.A. 2021-06-08 /pmc/articles/PMC8217650/ /pubmed/34168978 http://dx.doi.org/10.3389/fonc.2021.635237 Text en Copyright © 2021 Kim, Rajamanickam, Bernard, Chun, Wu, Martel, Sun, Redmond, Sanchez, Basho, McArthur and Page https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Oncology
Kim, Isaac
Rajamanickam, Venkatesh
Bernard, Brady
Chun, Brie
Wu, Yaping
Martel, Maritza
Sun, Zhaoyu
Redmond, William L.
Sanchez, Katherine
Basho, Reva
McArthur, Heather
Page, David B.
A Case Series of Metastatic Metaplastic Breast Carcinoma Treated With Anti-PD-1 Therapy
title A Case Series of Metastatic Metaplastic Breast Carcinoma Treated With Anti-PD-1 Therapy
title_full A Case Series of Metastatic Metaplastic Breast Carcinoma Treated With Anti-PD-1 Therapy
title_fullStr A Case Series of Metastatic Metaplastic Breast Carcinoma Treated With Anti-PD-1 Therapy
title_full_unstemmed A Case Series of Metastatic Metaplastic Breast Carcinoma Treated With Anti-PD-1 Therapy
title_short A Case Series of Metastatic Metaplastic Breast Carcinoma Treated With Anti-PD-1 Therapy
title_sort case series of metastatic metaplastic breast carcinoma treated with anti-pd-1 therapy
topic Oncology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8217650/
https://www.ncbi.nlm.nih.gov/pubmed/34168978
http://dx.doi.org/10.3389/fonc.2021.635237
work_keys_str_mv AT kimisaac acaseseriesofmetastaticmetaplasticbreastcarcinomatreatedwithantipd1therapy
AT rajamanickamvenkatesh acaseseriesofmetastaticmetaplasticbreastcarcinomatreatedwithantipd1therapy
AT bernardbrady acaseseriesofmetastaticmetaplasticbreastcarcinomatreatedwithantipd1therapy
AT chunbrie acaseseriesofmetastaticmetaplasticbreastcarcinomatreatedwithantipd1therapy
AT wuyaping acaseseriesofmetastaticmetaplasticbreastcarcinomatreatedwithantipd1therapy
AT martelmaritza acaseseriesofmetastaticmetaplasticbreastcarcinomatreatedwithantipd1therapy
AT sunzhaoyu acaseseriesofmetastaticmetaplasticbreastcarcinomatreatedwithantipd1therapy
AT redmondwilliaml acaseseriesofmetastaticmetaplasticbreastcarcinomatreatedwithantipd1therapy
AT sanchezkatherine acaseseriesofmetastaticmetaplasticbreastcarcinomatreatedwithantipd1therapy
AT bashoreva acaseseriesofmetastaticmetaplasticbreastcarcinomatreatedwithantipd1therapy
AT mcarthurheather acaseseriesofmetastaticmetaplasticbreastcarcinomatreatedwithantipd1therapy
AT pagedavidb acaseseriesofmetastaticmetaplasticbreastcarcinomatreatedwithantipd1therapy
AT kimisaac caseseriesofmetastaticmetaplasticbreastcarcinomatreatedwithantipd1therapy
AT rajamanickamvenkatesh caseseriesofmetastaticmetaplasticbreastcarcinomatreatedwithantipd1therapy
AT bernardbrady caseseriesofmetastaticmetaplasticbreastcarcinomatreatedwithantipd1therapy
AT chunbrie caseseriesofmetastaticmetaplasticbreastcarcinomatreatedwithantipd1therapy
AT wuyaping caseseriesofmetastaticmetaplasticbreastcarcinomatreatedwithantipd1therapy
AT martelmaritza caseseriesofmetastaticmetaplasticbreastcarcinomatreatedwithantipd1therapy
AT sunzhaoyu caseseriesofmetastaticmetaplasticbreastcarcinomatreatedwithantipd1therapy
AT redmondwilliaml caseseriesofmetastaticmetaplasticbreastcarcinomatreatedwithantipd1therapy
AT sanchezkatherine caseseriesofmetastaticmetaplasticbreastcarcinomatreatedwithantipd1therapy
AT bashoreva caseseriesofmetastaticmetaplasticbreastcarcinomatreatedwithantipd1therapy
AT mcarthurheather caseseriesofmetastaticmetaplasticbreastcarcinomatreatedwithantipd1therapy
AT pagedavidb caseseriesofmetastaticmetaplasticbreastcarcinomatreatedwithantipd1therapy